Skip to main content
SpringerLink
Log in

Treatment of Psoriasis

  • Chapter
Atlas of Psoriatic Arthritis

  • 2457 Accesses

Abstract

The treatment of psoriasis has long been a challenge to the dermatologist on several levels. Psoriasis does not respond in any predictable fashion to topical or systemic agents, and to date there are no clinical or laboratory measures to predict response to therapy in an individual. In clinical practice, emphasis on impact of the disease and its treatment on a patient’s quality of life and health should guide treatment choices. Severity of disease, including location and body surface area, response to previous therapies, medical history, concomitant medications, treatment goals, convenience of administration, and financial limitations, must all be considered carefully when choosing initial therapy. Because in any given patient severity and impact of disease will fluctuate over time and with different therapies, frequent reassessment of symptoms, treatment satisfaction, and short- and long-term side effects of therapy is a necessary approach.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fredriksson T, Pettersson U. Severe psoriasis —oral therapy with a new retinoid. Dermatologica 1978;157:238–244.

    Article  PubMed  CAS  Google Scholar 

  2. Naldi L, Svensson A, Diepgen T et al. European Dermato-Epidemiology Network. Randomized clinical trials for psoriasis 1977–2000 the EDEN survey. J Invest Dermatol 2003;120:738–741.

    Article  PubMed  CAS  Google Scholar 

  3. Krueger GG. New method being developed for assessing psoriasis. National Psoriasis Foundation Forum 1999;5:4–5.

    Google Scholar 

  4. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. J Am Acad Dermatol 2004;51:563–569.

    Article  PubMed  Google Scholar 

  5. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) —a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210–216.

    Article  PubMed  CAS  Google Scholar 

  6. Finlay AY, Kelly SE. Psoriasis —an index of disability. Clin Exp Dermatol 1987;12:8–11.

    Article  PubMed  CAS  Google Scholar 

  7. Koo J, Menter A, Lebwohl M et al. The relationship between quality of life and disease severity: results from a large cohort of mild, moderate, and severe psoriasis patients. Br J Dermatol 2002;147:1078.

    Google Scholar 

  8. Koo J, Kozma CM, Menter A et al. Development of a disease specific quality of life questionnaire —the 12-item Psoriasis Quality of Life Questionnaire (PQOL-12). Presented at: 61st Annual Meeting of the American Academy of Dermatology. San Francisco, CA. March 21–26, 2003.

    Google Scholar 

  9. Katz HI, Hien NT, Prawer SE et al. Superpotent topical steroid treatment of psoriasis vulgaris —clinical efficacy and adrenal function. J Am Acad Dermatol 1987;16:804–811.

    PubMed  CAS  Google Scholar 

  10. Bruce S, Epinette WW, Funicella T et al. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol 1994;31(5, Pt 1):755–759.

    PubMed  CAS  Google Scholar 

  11. Lebwohl M, Siskin SB, Epinette W et al. A multicenter trial of calcipotriene ointment and halo-betasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 1996;35(2, Pt 1):268–269.

    Article  PubMed  CAS  Google Scholar 

  12. Lebwohl M, Yoles A, Lombardi K et al. Calcipotriene ointment and halo-betasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol 1998;39:447–450.

    Article  PubMed  CAS  Google Scholar 

  13. Singh S, Reddy DC, Pandey SS. Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks. J Am Acad Dermatol 2000;43(1, Pt 1):61–65.

    Article  PubMed  CAS  Google Scholar 

  14. Ramsay CA, Schwartz BE, Lowson D et al. Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group. Dermatology 2000;200:17–24.

    Article  PubMed  CAS  Google Scholar 

  15. van de Kerkhof PC, Cambazard F, Hutchinson PE et al. The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis. Br J Dermatol 1998;138:84–89.

    Article  PubMed  Google Scholar 

  16. Grossman RM, Thivolet J, Claudy A et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol 1994;31:68–74.

    PubMed  CAS  Google Scholar 

  17. Kokelj F, Torsello P, Plozzer C. Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 1998;10:143–146.

    Article  PubMed  CAS  Google Scholar 

  18. Duvic M, Asano AT, Hager C et al. The pathogenesis of psoriasis and the mechanism of action of tazarotene. J Am Acad Dermatol 1998;39(4, Pt 2):S129–S133.

    Article  PubMed  CAS  Google Scholar 

  19. Krueger GG, Drake LA, Elias PM et al. The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Arch Dermatol 1998;134:57–60.

    Article  PubMed  CAS  Google Scholar 

  20. Persaud A, Bershad S, Lamba S et al. Short contact tazarotene therapy for psoriasis. Poster presented at: American Academy of Dermatology. Nashville, TN, 2000.

    Google Scholar 

  21. Koo JY, Martin D. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol 2001;40:210–212.

    Article  PubMed  CAS  Google Scholar 

  22. Lebwohl M, Lombardi K, Tan MH. Duration of improvement in psoriasis after treatment with tazarotene 0. 1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments. Int J Dermatol 2001;40:64–66.

    Article  PubMed  CAS  Google Scholar 

  23. Lowe NJ. Optimizing therapy: tazarotene in combination with phototherapy. Br J Dermatol 1999;140(Suppl 54):8–11.

    Article  PubMed  CAS  Google Scholar 

  24. Koo JY, Lowe NJ, Lew-Kaya DA et al. Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol 2000;43(5, Pt 1):821–828.

    Article  PubMed  CAS  Google Scholar 

  25. Behrens S, Grundmann-Kollmann M, Schiener R et al. Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. J Am Acad Dermatol 2000;42:493–495.

    Article  PubMed  CAS  Google Scholar 

  26. Shelk J, Morgan P. Narrow-band UVB: a practical approach. Dermatol Nurs 2000;12:407–411.

    PubMed  CAS  Google Scholar 

  27. Feldman SR, Mellen BG, Housman TS et al. Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study. J Am Acad Dermatol 2002;46:900–906.

    Article  PubMed  Google Scholar 

  28. Gubner R. Effect of aminopterin on epithelial tissues. Arch Dermatol 1951;64:699.

    Google Scholar 

  29. Heydendael VM, Spuls PI, Opmeer BC et al. Methotrexate versus cyclosporine in moderate-tosevere chronic plaque psoriasis. N Engl J Med 2003;349:658–665.

    Article  PubMed  CAS  Google Scholar 

  30. Granelli-Piperno A, Nolan P, Inaba K et al. The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promoter. J Exp Med 1990;172:1869–1872.

    Article  PubMed  CAS  Google Scholar 

  31. Ellis CN, Gorsulowsky DC, Hamilton TA et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 1986;256:3110–3116.

    Article  PubMed  CAS  Google Scholar 

  32. Tanew A, Guggenbichler A, Honigsmann H et al. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol 1991;25:682–684.

    PubMed  CAS  Google Scholar 

  33. Lowe NJ, Prystowsky JH, Bourget T et al. Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 1991;24:591–594.

    Article  PubMed  CAS  Google Scholar 

  34. Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 2003;49:S44–S50.

    Article  PubMed  Google Scholar 

  35. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol 2002;138:657–663.

    Article  PubMed  CAS  Google Scholar 

  36. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002;46:1–23.

    Article  PubMed  Google Scholar 

  37. Leonardi CL, Powers JL, Metheson RT et al. For the Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014–2022.

    Article  PubMed  CAS  Google Scholar 

  38. Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304–1312.

    Article  PubMed  CAS  Google Scholar 

  39. Tyring S, Poulin Y, Langley R et al. A 96-week phase 3 study of safety and efficacy of etanercept 50 mg twice weekly in patients with psoriasis. Presented at: 64th Annual Meeting of the American Academy of Dermatology; San Francisco, CA; March 3–7, 2006; Poster P39.

    Google Scholar 

  40. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderateto-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367–1374.

    Article  PubMed  CAS  Google Scholar 

  41. Langley R, Leonardi C, Okun M. Long-term safety and efficacy of adalimumab in psoriasis. Presented at: European Academy of Dermatology and Venereology Spring Symposium. Lapland, Finland; February 9–12, 2006.

    Google Scholar 

  42. Amevive® (Alefacept) Product Information. Biogen Inc., MA, USA.

    Google Scholar 

  43. Majeau GR, Meier W, Jimmo B et al. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T-cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol 1994;152:2753–2767.

    PubMed  CAS  Google Scholar 

  44. Miller GT, Hochman PS, Meier W et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T-cell responses. J Exp Med 1993;178:211–222.

    Article  PubMed  CAS  Google Scholar 

  45. Krueger GG, Papp KA, Stough DB et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002;47:821–833.

    Article  PubMed  Google Scholar 

  46. Gordon KB, Langley RG. Remitive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol 2003;2:624–628.

    PubMed  Google Scholar 

  47. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248–255.

    Article  PubMed  CAS  Google Scholar 

  48. Krueger GG, Papp KA, Stough DB et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002;47:821–833.

    Article  PubMed  Google Scholar 

  49. Lebwohl M, Christophers E, Langley R et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719–727.

    Article  PubMed  CAS  Google Scholar 

  50. Krueger GG. Current concepts and review of alefacept in the treatment of psoriasis. Dermatol Clin 2004;22:407–426, viii.

    Article  PubMed  CAS  Google Scholar 

  51. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 1999;341:1817–1828.

    Article  PubMed  CAS  Google Scholar 

  52. Gottlieb AB, Matheson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627–1632.

    Article  PubMed  CAS  Google Scholar 

  53. Werther WA, Gonzalez TN, O’Connor SJ et al. Humanization of an anti-lymphocyte function-associated antigen (LFA-1) monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 1996;157:4986–4995.

    PubMed  CAS  Google Scholar 

  54. Lebwohl M, Tyring SK, Hamilton TK et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004–2013.

    Article  PubMed  CAS  Google Scholar 

  55. Gordon KB, Papp KA, Hamilton TK et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003;290:3073–3080.

    Article  PubMed  CAS  Google Scholar 

  56. Leonardi CL, Papp KA, Gordon KB et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005;52(3, Pt 1):425–433.

    Article  PubMed  Google Scholar 

  57. Menter A, Gordon K, Carey W et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005;141:31–38.

    Article  PubMed  CAS  Google Scholar 

  58. Marano CW, Evans R, Guzzo C et al. Immunogenicity of infliximab (Remicade safety in patients with severe plaque-type psoriasis. Presented at: 61st Annual Meeting of the American Academy of Dermatology. San Francisco, CA; March 21–26, 2003.

    Google Scholar 

  59. Menter A, Gordon K, Leonardi C et al. Adalimumab efficacy and safety results in patients with moderate to severe chronic plaque psoriasis with and without psoriatic arthritis. Poster presented at: American Academy of Dermatology Annual Meeting. New Orleans, LA; February 18–22, 2005. Poster 2713.

    Google Scholar 

  60. Antoni CE, Kavanaugh A, Kirkham B et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52:1227–1236.

    Article  PubMed  CAS  Google Scholar 

  61. Antoni C, Krueger GG, de Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;54:1227–1236.

    Google Scholar 

  62. Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534–542.

    Article  PubMed  Google Scholar 

  63. Gottlieb AB, Chaudhari U, Mulcahy et al. Infliximab mono-therapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003;48:829–835.

    Article  PubMed  Google Scholar 

  64. Chaudhari U, Romano P, Mulcahy LD et al. Efficacy and safety of infliximab monotherapy for plaquetype psoriasis: a randomised trial. Lancet 2001;357:1842–1847.

    Article  PubMed  CAS  Google Scholar 

  65. Wagner CL, Schantz A, Barnathan E et al. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol 2003;2:37–53.

    Google Scholar 

  66. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552–1563.

    Article  PubMed  CAS  Google Scholar 

  67. Leonardi CL. Current concepts and review of efalizumab in the treatment of psoriasis. Dermatol Clin 2004;22:427–435.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Utah Psoriasis Initiative, University of Utah, Salt Lake City, UT, USA

    Gerald G. Krueger & Kristina P. Callis

Authors
  1. Gerald G. Krueger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kristina P. Callis
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Medicine, University of Washington, Seattle, WA, USA

    P. J. Mease MED (RHUUH)

  2. Academic Unit of Musculoskeletal and Rehabilitation Medicine, University of Leeds, Leeds, UK

    P. S. Helliwell DM, PhD, FRCP

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag London Limited

About this chapter

Cite this chapter

Krueger, G.G., Callis, K.P. (2008). Treatment of Psoriasis. In: Mease, P.J., Helliwell, P.S. (eds) Atlas of Psoriatic Arthritis. Springer, London. https://doi.org/10.1007/978-1-84628-897-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-897-5_8

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-896-8

  • Online ISBN: 978-1-84628-897-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation